Bicara Therapeutics Inc. ("Bicara"), an associate company of Biocon Limited, has on December 12, 2023, completed its US$165 Million Series C funding. Consequent to this infusion of Series C funding and post allotment of shares by Bicara, the Company''s shareholding in Bicara on fully diluted basis will fall below 20% and thereby, Bicara will cease to be an associate company of Biocon Limited.